UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ALL-394: Hyper-CVAD vs. BFM-Like Regimens in Adult Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia: A Single-Center Experience

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S172-S172

2020

Volltextzugriff (PDF)

TCL-695 A Rare Case of Extranodal NK/T-Cell Lymphoma, Transformation to T-ALL

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S526-S526

2024

Volltextzugriff (PDF)

ALL-748 Venetoclax Added to Hyper-CVAD-Nelarabine and Pegylated Asparagine Improves Outcomes in Patients With T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S283-S283

2024

Volltextzugriff (PDF)

Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome–positive acute lymphoblastic leukemia treated with hyper‐CVAD and dasatinib

Cancer, 2021-08, Vol.127 (15), p.2641-2647

2021

Volltextzugriff (PDF)

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

British journal of haematology, 2010-07, Vol.150 (2), p.200-208

2010

Volltextzugriff (PDF)

Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center

British journal of haematology, 2016-01, Vol.172 (1), p.80-88

2016

Volltextzugriff (PDF)

Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults

Leukemia research, 2024-02, Vol.137, p.107438-107438, Article 107438

2024

Volltextzugriff (PDF)

Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma

British journal of haematology, 2021-03, Vol.192 (6), p.1011-1014

2021

Volltextzugriff (PDF)

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

Cancer, 2006-04, Vol.106 (7), p.1569-1580

2006

Volltextzugriff (PDF)

Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemotherapy

European journal of haematology, 2023-02, Vol.110 (2), p.168-176

2023

Volltextzugriff (PDF)

Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm

Journal of pediatric hematology/oncology, 2023-11, Vol.45 (8), p.e1001-e1004

2023

Volltextzugriff (PDF)

Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia

Cancer, 2004-12, Vol.101 (12), p.2788-2801

2004

Volltextzugriff (PDF)

Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center

Leukemia research, 2022-08, Vol.119, p.106885-106885, Article 106885

2022

Volltextzugriff (PDF)

Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia

European journal of haematology, 2023-12, Vol.111 (6), p.863-871

2023

Volltextzugriff (PDF)

Outcome evaluation of patients with acute lymphocytic leukemia treated by Hyper-CVAD chemotherapy regimen in Omid Hospital, Isfahan, Iran

Majallah-i Danishkadah-'i Pizishki, 2022-12, Vol.80 (10), p.835-841

2022

Volltextzugriff (PDF)

ALL-326: Low Incidence of Central Nervous System (CNS) Relapse with Hyper-CVAD-R Regimen in Adults with Burkitt Lymphoma/Leukemia (BL) and High-Grade B-Cell Lymphoma (HGBCL)

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S170-S171

2020

Volltextzugriff (PDF)

Filgrastim-induced hemophagocytic lymphohistiocytosis in a patient with mantle cell lymphoma: A case report

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2024-02, Vol.30 (2), p.150-153

2024

Volltextzugriff (PDF)

Evaluation of Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Hyper-CVAD Treatment in Seyyed Al-Shohada Hospital: Isfahan, 2014-2019

International journal of hematology- oncology and stem cell research, 2024, Vol.18 (1), p.47-52

2024

Volltextzugriff (PDF)

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma

Leukemia & lymphoma, 2019-03, Vol.60 (4), p.904-911

2019

Volltextzugriff (PDF)

ALL-473 Dilemma of Diagnosing and Treating BPDCN; Case Report With Clinicopathological Correlation

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S205-S206

2022

Volltextzugriff (PDF)

Síndrome de encefalopatía posterior reversible en un paciente con hyper-CVAD. Reporte de un caso

Medicina Clínica Práctica, 2022-07, Vol.5 (3), p.100326

2022

Volltextzugriff (PDF)

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T‐cell lymphoma

British journal of haematology, 2015-11, Vol.171 (4), p.509-516

2015

Volltextzugriff (PDF)

Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience

EJHaem, 2021-11, Vol.2 (4), p.774-784

2021

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(79)

Publikationsform

Artikel
(89)
Buchkapitel
(4)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

Cancer
(14)
Clinical Lymphoma, Myeloma And Leukemia
(10)
Leukemia & Lymphoma
(7)
British Journal Of Haematology
(6)
Leukemia Research
(4)
Oncotargets And Therapy
(4)
Rinsho Ketsueki
(4)
Rinshō Ketsueki
(4)
Annals Of Hematology
(3)
Chemotherapy
(2)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis

ALL-394: Hyper-CVAD vs. BFM-Like Regimens in Adult Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia: A Single-Center Experience

TCL-695 A Rare Case of Extranodal NK/T-Cell Lymphoma, Transformation to T-ALL

ALL-748 Venetoclax Added to Hyper-CVAD-Nelarabine and Pegylated Asparagine Improves Outcomes in Patients With T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome–positive acute lymphoblastic leukemia treated with hyper‐CVAD and dasatinib

Ten‐year follow‐up after intense chemoimmunotherapy with Rituximab‐HyperCVAD alternating with Rituximab‐high dose methotrexate/cytarabine (R‐MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

Rituximab plus hyper‐CVAD alternating with MTX/Ara‐C in patients with newly diagnosed mantle cell lymphoma: 15‐year follow‐up of a phase II study from the MD Anderson Cancer Center

Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults

Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

Real‐world utility of early measurable residual disease assessments by multi‐parametric flow cytometry in adult patients with B‐lymphoblastic leukemia receiving Hyper‐CVAD induction chemotherapy

Frontline Hyper-CVAD Plus Venetoclax for Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm

Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia

Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center

Hyper‐CVAD versus dose‐adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia

Outcome evaluation of patients with acute lymphocytic leukemia treated by Hyper-CVAD chemotherapy regimen in Omid Hospital, Isfahan, Iran

ALL-326: Low Incidence of Central Nervous System (CNS) Relapse with Hyper-CVAD-R Regimen in Adults with Burkitt Lymphoma/Leukemia (BL) and High-Grade B-Cell Lymphoma (HGBCL)

Filgrastim-induced hemophagocytic lymphohistiocytosis in a patient with mantle cell lymphoma: A case report

Evaluation of Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia (ALL) Receiving Hyper-CVAD Treatment in Seyyed Al-Shohada Hospital: Isfahan, 2014-2019

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper‐CVAD‐based regimens

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma

ALL-473 Dilemma of Diagnosing and Treating BPDCN; Case Report With Clinicopathological Correlation

Síndrome de encefalopatía posterior reversible en un paciente con hyper-CVAD. Reporte de un caso

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T‐cell lymphoma

Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience

Suchergebnisse filtern